Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07041099 · ClinicalTrials.gov registry record · Phase 1
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
A Phase 1 study of Sjogren's Syndrome and Sjogren Disease, sponsored by Cullinan Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 11
- Study locations
NCT07041099: Recruiting Phase 1 study of Sjogren's Syndrome and Sjogren Disease, sponsored by Cullinan Therapeutics.
NCT07041099 is a Phase 1 study of Sjogren's Syndrome and Sjogren Disease that is actively recruiting participants, run by Cullinan Therapeutics. The registered enrollment target is 36 participants, below the 286-participant average among 20 other Sjogren's Syndrome trials with a reported enrollment target (87% lower). The trial reports 11 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07041099, a Phase 1 study of Sjogren's Syndrome and Sjogren Disease, is actively recruiting participants, sponsored by Cullinan Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 11
- Study locations
Study Summary
A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.
Primary Outcome
Incidence and severity of adverse events (AEs), serious AEs (SAEs), AEs of special interest (AESIs).
Conditions Studied
Interventions
- DRUG CLN-978
Study Locations (11)
Other
- Cullinan Investigative Site - Brest
- Cullinan Investigative Site - Le Kremlin-Bicêtre
- Cullinan Investigative Site - Strasbourg
- Cullinan Investigative Site - Erlangen
- Cullinan Investigative Site - Hanover
- Cullinan Investigative Site - Roma
Texas
- Cullinan Investigative Site - Plano
- Cullinan Investigative Site - Webster
Florida
- Cullinan Investigative Site - Orlando
Tennessee
- Cullinan Investigative Site - Memphis
Utah
- Cullinan Investigative Site - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2029-03-15 |
| Phase | Phase 1 |
What NCT07041099 shows while recruiting
NCT07041099 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 286-participant average among 20 other Sjogren's Syndrome trials with a reported enrollment target (87% lower).
The record links to 3 conditions, with Sjogren's Syndrome appearing as the primary indexed condition, and to 1 intervention - of which CLN-978 is the first listed.
NCT07041099 lists 11 locations in 5 states (Other, Texas, Florida).
Frequently Asked Questions
What is clinical trial NCT07041099 about?
NCT07041099 is a clinical study titled "A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease". A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.
What is the current status of trial NCT07041099?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2025-10-01. Estimated completion is 2029-03-15.
What conditions does trial NCT07041099 study?
This clinical trial studies the following conditions: Sjogren's Syndrome, Sjogren Disease, Sjögren.
What interventions are being tested in trial NCT07041099?
The interventions under investigation include: CLN-978 (DRUG).
Who is sponsoring clinical trial NCT07041099?
This trial is sponsored by Cullinan Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07041099 being conducted?
This trial has 11 study locations across Florida, Tennessee, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sjogren's Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07041099's enrollment target sits among peer trials
36 14th of 20 higher than 7 of 20 other Sjogren's Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sjogren's Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome
ACTIVE NOT RECRUITING · Phase 1
-
Anti-CD20 Antibody Therapy for Sjogren's Syndrome
COMPLETED · Phase 1
-
An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness
COMPLETED · Phase 1
-
Omalizumab for Lupus
COMPLETED · Phase 1
-
Rheumatology Diet Study
RECRUITING
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI